EUCTR2022-001294-31-AT进行中（未招募）1 期
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) - CROSSING
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 360
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant must be 12 to 80 years of age inclusive, at the time of signing the informed consent/assent.
- •2. Weight = 40 kg at Visit 1
- •3. Established diagnosis of EoE with a previous EGD and esophageal biopsy confirming a diagnosis of EoE.
- •4. Participants who have symptomatic EoE as defined by a history of on average at least 2 episodes of dysphagia (any severity of food going down slowly or being stuck in the throat) per week in the 4 weeks prior to Visit 1.
- •5. Must remain on a stabilized diet for at least 8 weeks prior to Visit 1 and during the course of the study (stable diet is defined as no initiation of single or multiple elimination diets or reintroduction of previously eliminated food groups).
- •6. May be on any background medication for EoE, for example PPI and/or STC, during the course of the study, as long as background medications have been stable for at least 8 weeks prior to the
- •screening/run-in period (Visit 1) and there is agreement not to change background medication or dosage unless medically indicated, during the screening/run-in and treatment period.
- •7. Participants currently leukotriene inhibitors and/or steroid treatments for asthma or allergies that are inhaled or administered intranasally, must report a stable dose for at least 4 weeks prior to the screening/run-in period (Visit 1).
- •8. If a medication for EoE (including PPI and/or STC) is discontinued prior to the screening/run-in, there should be a washout period of at least 8 weeks prior to Visit 1. Discontinuation of any marketed biologic (monoclonal or polyclonal antibody) should have a washout period of 4 months or 5 half-lives prior to Visit 1, whichever is longer.
- •9. Participants must have previously documented standard of care treatment, which could include PPI and/or STC and/or diet.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 36
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 314
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1. Other gastrointestinal disorders such as active Helicobacter pylori infection, history of achalasia, esophageal varices, Crohn's disease, ulcerative colitis, inflammatory bowel disease, celiac disease, eosinophilic enteritis, colitis, diverticulitis, irritable bowel syndrome, or other clinically significant gastrointestinal conditions as per Investigator discretion.
- •2.Esophageal stricture that prevents the easy passage of a standard endoscope or any critical esophageal stricture that requires dilation at screening.
- •3. Use of a feeding tube, or having a pattern of not eating solid food = 3
- •days of the week. Solid food is defined as food that requires chewing before swallowing.
- •4. Hypereosinophilic syndrome
- •5. EGPA vasculitis
- •6. Esophageal dilation performed within 8 weeks prior to screening.
研究者
相似试验
进行中（未招募）
1 期
Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Subjects with Major Depressive DisorderMedDRA version: 18.0Level: LLTClassification code 10025454Term: Major depressive disorder, recurrent episodeSystem Organ Class: 100000004873Major Depressive DisorderEUCTR2015-000306-18-FIMinerva Neurosciences, Inc.80
未知
3 期
A Phase III Study of SM-13496 in Patients with Bipolar I Depression.JPRN-jRCT2080222269Sumitomo Dainippon Pharma Co., Ltd.501
进行中（未招募）
不适用
This is a multinational study comparing the efficacy and safety of two medicines , solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder.MedDRA version: 17.1Level: LLTClassification code 10059617Term: Overactive bladderSystem Organ Class: 100000004857Overactive BladderEUCTR2012-005735-91-EEAstellas Pharma Europe B.V.7,000
已完成
Unknown
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of Plant-based extract mixture on Hangover ImprovementMental and behavioural disordersKCT0008402H Plus Yangji Hospital80
进行中（未招募）
不适用
This is a multinational study comparing the efficacy and safety of two medicines , solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder.Overactive BladderEUCTR2012-005735-91-LVAstellas Pharma Europe B.V.4,500